Permanent prostate brachytherapy has been increasingly used as a highly curative treatment for clinically localized prostate cancer. Many brachytherapy studies have reported favorable long-term biochemical outcomes. with a minimal morbidity that compares with surgery or external beam radiotherapy. So I-125 seed implant must be a best treatment option for a low risk group. There are some contraindications or limitation for brachytherapy. There is a learning curve as well. Combined treatment with external beam or hormone treatment may be necessary for intermediate or high risk groups. It is possible that high-quality brachytherapy may have more favorable results.
|ジャーナル||Japanese Journal of Clinical Radiology|
|出版ステータス||Published - 2005 6 13|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging